XEN-101 / Xeno Biosci - LARVOL DELTA

A Phase 1b Study to Evaluate the Safety of XEN-101 (clinicaltrials.gov) - P1 | N=33 | Terminated | Sponsor: Xeno Biosciences | Data were reviewed after the first 23 patients had completed scheduled dosing and there was no signal of efficacy for change in body weight. This clinical trial has been determined to be futile.

Trial termination • Genetic Disorders • Obesity

A Phase 1b Study to Evaluate the Safety of XEN-101 (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Xeno Biosciences

New P1 trial • Genetic Disorders • Obesity

A Phase 1 Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of XEN-101 (clinicaltrials.gov) - P1 | N=97 | Completed | Sponsor: Xeno Biosciences | Recruiting ➔ Completed

Trial completion

A Phase 1 Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of XEN-101 (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Xeno Biosciences

New P1 trial